This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.
Professor Carole Longson, director of NICE's health technology evaluation centre, said: Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when compared
The European Commission ( EC) has approved Takeda's Entyvio ( vedolizumab) to treat adults with ulcerative colitis and Crohn's disease and Boehringer Ingelheim/Lilly's Jardiance ( empagliflozin), which adds to the growing list of treatments
FDA clears Takeda's vedolizumab for inflammatory bowel disease. Entyvio licensed for patients who have not responded to current therapies. ... The FDA approved Entyvio ( vedolizumab) to treat adults with moderate to severe ulcerative colitis ( UC) and
FDA panel backs Takeda's inflammatory bowel disease drug. Vedolizumab on course for US approval to treat Crohn's disease and ulcerative colitis. ... Takeda's Millennium Pharmaceuticals unit took a step closer to US approval for one of its top pipeline
FDA grants priority review to Takeda's colitis drug. Accelerates review time for vedolizumab. ... One of Takeda's top pipeline prospects - vedolizumab for ulcerative colitis ( UC) - has been given a priority review by the US Food and Drug Administration (
Phase III data raise hopes for Takeda's vedolizumab. Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease. ... Data from phase III trials of Takeda's inflammatory bowel disease ( IBD) drug vedolizumab suggests the company's
More from news
Approximately 7 fully matching, plus 7 partially matching documents found.
There's prostate cancer drug orteronel ( TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel ( TAK-700),